Alembic Pharma Peer Comparison

NSE: APLLTD | BSE: 533573

₹813.45

₹-10.55 (-1.28%)

As on 28-Aug-2026IST

Market cap

₹16,000 Cr

Revenue (TTM)

₹7,784 Cr

P/E Ratio

23.1

P/B Ratio

2.7

Div. Yield

1.5 %

Edit

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	16,000	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	7,784	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	688.47	414.00	288.22	-371.81	387.35
Net Margin (%)	8.77	11.23	14.79	-3.93	26.01
RoE (%)	14.02	8.38	29.77	-3.85	25.18
Price to Earnings	23.07	78.49	103.71	--	69.57
Price-To-Book	2.74	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	7,344.90	3,373.00	1,753.96	8,869.08	1,006.88
Total Income	7,399.78	3,510.00	1,762.66	9,111.51	1,023.80
Total Expenditure	6,226.90	2,747.00	1,354.69	7,976.59	774.80
EBITDA	1,118.00	626.00	399.26	892.49	232.07
Depreciation	318.55	227.00	45.26	831.24	26.62
EBIT	799.45	399.00	354.00	61.25	205.45
Interest	93.63	213.00	42.17	340.80	6.22
Other Income	54.88	137.00	8.70	242.43	16.93
Exceptional Items	-66.99	-85.00	--	-196.14	--
Profit before Tax	693.95	238.00	320.53	-176.06	216.16
Provision for Tax	23.12	39.00	73.80	149.88	55.75
Profit after Tax	670.83	199.00	246.74	-325.94	160.42

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	5,674.81	4,940.00	1,288.82	8,162.62	1,309.63
Minority Interest	-5.83	341.00	0.00	--	10.45
Non-Current Liabilities	230.16	1,235.00	189.02	4,529.41	26.93
Current Liabilities	2,686.87	1,622.00	835.87	4,874.74	202.25
Total Liabilities	8,855.62	8,578.00	2,326.71	17,723.32	1,549.26

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	3,920.38	5,441.00	631.90	10,258.66	757.63
Current Assets	4,635.63	2,606.00	1,681.81	7,308.11	791.64
Total Assets	8,855.62	8,578.00	2,326.71	17,723.32	1,549.26
Total Debt*	1,360.85	2,125.00	259.37	5,495.48	8.18
Net Current Assets	1,948.76	984.00	845.94	2,433.37	589.39
Contingent Liabilities	160.39	768.26	19.09	95.72	15.38

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	782.73	390.00	205.05	1,652.60	118.34
Cash Flow from Investing Activities	-506.06	-241.00	-409.72	-826.03	-223.94
Cash from Financing Activities	-163.78	-54.00	283.07	-38.98	261.12
Net Cash Inflow / Outflow	112.89	95.00	78.39	787.59	155.52

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	11.74	6.79	29.22	1.24	20.14
ROE (%)	12.35	4.29	27.84	-4.04	16.19
ROA (%)	8.23	2.53	13.11	-1.98	12.13
EBIT Margin (%)	15.97	22.62	23.26	12.80	24.73
Net Margin (%)	9.07	5.67	14.00	-3.58	15.67
Cash Profit Margin (%)	6.94	10.98	7.71	4.80	18.58

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	10.08	11.99	36.57	-3.08	40.34
EBIT Growth (%)	11.62	67.69	52.29	-28.15	83.12
Net Profit Growth (%)	15.26	449.12	83.64	-457.66	229.35
EPS Growth (%)	15.66	553.20	71.44	-456.91	67.16
Book Value Growth (%)	9.32	13.47	144.31	0.33	94.96

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	19.28	89.54	51.69	0.00	62.97
Price / Book Value	2.29	3.87	10.14	2.24	15.26
Dividend Yield (%)	1.81	0.00	0.19	0.00	0.06
EV/EBITDA	12.08	27.45	31.05	19.72	79.31
Market Cap (₹ Cr)	13,008.55	19,071.62	12,753.19	18,108.89	19,988.69

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.24	0.43	0.21	0.68	0.01
Short term debt to equity ratio	0.21	0.09	0.05	0.09	0.01
Current Ratio	1.73	1.61	2.01	1.50	3.91
Quick Ratio	0.79	1.06	1.14	0.87	3.02
Interest Coverage	8.41	2.12	8.60	0.48	35.76

	Alembic Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	19.96	17.43	29.00	24.33	28.85
Asset Turnover	1.75	0.49	2.01	0.64	0.76
Receivable days	36.70	58.75	40.13	78.20	90.06
Inventory Days	61.45	75.82	60.29	93.30	61.02
Payable days	157.72	186.21	232.47	226.14	96.06
Cash Conversion Cycle	-59.57	-51.64	-132.04	-54.64	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.